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Abstract
Chronic low-grade inflammation in adipose tissue often accompanies obesity, leading to insulin resistance and increasing
the risk for metabolic diseases. MAP3K8 (TPL2/COT) is an important signal transductor and activator of pro-inflammatory
pathways that has been linked to obesity-induced adipose tissue inflammation. We used human adipose tissue biopsies to
study the relationship of MAP3K8 expression with markers of obesity and expression of pro-inflammatory cytokines (IL-1b,
IL-6 and IL-8). Moreover, we evaluated obesity-induced adipose tissue inflammation and insulin resistance in mice lacking
MAP3K8 and WT mice on a high-fat diet (HFD) for 16 weeks. Individuals with a BMI .30 displayed a higher mRNA
expression of MAP3K8 in adipose tissue compared to individuals with a normal BMI. Additionally, high mRNA expression
levels of IL-1b, IL-6 and IL-8, but not TNF -a, in human adipose tissue were associated with higher expression of MAP3K8.
Moreover, high plasma SAA and CRP did not associate with increased MAP3K8 expression in adipose tissue. Similarly, no
association was found for MAP3K8 expression with plasma insulin or glucose levels. Mice lacking MAP3K8 had similar
bodyweight gain as WT mice, yet displayed lower mRNA expression levels of IL-1b, IL-6 and CXCL1 in adipose tissue in
response to the HFD as compared to WT animals. However, MAP3K8 deficient mice were not protected against HFD-
induced adipose tissue macrophage infiltration or the development of insulin resistance. Together, the data in both human
and mouse show that MAP3K8 is involved in local adipose tissue inflammation, specifically for IL-1b and its responsive
cytokines IL-6 and IL-8, but does not seem to have systemic effects on insulin resistance.
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Introduction
Obesity is characterized by chronic low-grade inflammation
arising from the adipose tissue [1]. This inflammatory trait mainly
results from resident or infiltrating immune cells into the adipose
tissue and is associated with insulin resistance and metabolic
diseases such as type 2 diabetes mellitus [2]. In response to pro-
inflammatory stimuli, immune receptors activate signalling path-
ways, such as protein kinase like IkB kinase (IKK) and extra-
cellular signal-regulated kinase (ERK). Stimulation of these
pathways leads to activation of NF-kB and JNK transcription
factors, resulting in transcription of pro-inflammatory genes
including TNF-a, IL-6, IL-1b, and CCL2 [3]. These pathways
have been recognized to play a pivotal role in instigating a local
inflammatory reaction in the adipose tissue of obese patients,
secondarily affecting the insulin signalling pathway [4–6].
Serine threonine mitogen activated protein kinase kinase kinase
8 (MAP3K8), in mice also called tumor progression locus 2 (TPL2)
and in humans called Cancer Osaka Thyroid (COT), activates
ERK-1/2 [7,8]. In quiescent state, MAP3K8 forms a complex
with A20-binding inhibitor of NF-kB (ABIN-2) and p105 NF-kB,
precursor of the NF-kB transcription factor. It can be activated by
pro-inflammatory stimuli, such as TNF-a, IL-1b and LPS.
MAP3K8 knockout mice that are exposed to LPS/D-galactos-
amine-induced pathology are protected against endotoxin shock,
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showing that MAP3K8 is an essential protein in directing
inflammatory responses [9]. The role of MAP3K8 in regulating
the inflammatory trait of obesity is not fully clear. The function of
MAP3K8 in obesity-induced inflammation has been studied
previously.
One study reported that MAP3K8 is upregulated in adipose
tissue in response to IL-1ß and TNF-a and mediates lipolysis
induced by these cytokines [10]. Another study reported that
MAP3K8 regulates obesity-associated inflammation and insulin
resistance. MAP3K8 deficient mice showed a reduction of high fat
diet (HFD)-induced adipose tissue inflammation and a reduced
expression of inflammatory markers, as well as improved insulin
sensitivity [11]. These results were not confirmed in a study that
found contradictory results after conducting a similar high fat diet
intervention study. The authors showed that MAP3K8 deficient
mice were not protected against the detrimental effects of diet-
induced obesity [12]. No differences in mRNA levels of several
markers of adipose tissue inflammation or whole body glucose or
insulin tolerance were observed in mice. Moreover, MAP3K8 was
not up-regulated in adipose tissue due to HFD-feeding.
Considering these contradictory data in the literature, we aimed
to illuminate the role of MAP3K8 using a complementary
approach combining murine studies with assessment of the role
of MAP3K8 in human adipose tissue. We found that human
MAP3K8 expression in adipose tissue is indeed associated with
obesity. However, using mice lacking MAP3K8, our data show a
redundant role for MAP3K8 in obesity-associated metabolic
dysfunction. Local adipose tissue inflammation was only mildly
influenced. Moreover, human adipose tissue biopsies show that
MAP3K8 expression in adipose tissue associates with mRNA
levels of IL-1b, IL-6 and IL-8, but not with systemic metabolic
parameters. Together these data suggest that MAP3K8 partially
affects pro-inflammatory gene expression in adipose tissue, yet




Subcutaneous adipose tissues were obtained from 70 healthy
donors subjects with a broad range of BMI. The measurements
were carried out in the first and last quartile. The group was
divided in low BMI and high BMI (BMI ,25, n= 33, BMI .30,
n = 18), low and high plasma insulin levels (concentration ,
5 mU/L, n= 22,.8 mU/L, n= 28); low and high plasma glucose
levels (concentration ,5 mM, n= 30, .5 mM, n= 40); low and
high HOMA-IR levels (,2, n= 40, .2 n=26); adipocyte cell size
(diameter in mM, smallest and largest quartile n = 36). HOMA-IR
was calculated by: (glucose * insulin plasma levels)/22.5. For
association with mRNA levels of IL-1b, IL-6, IL-8 and TNFa to
MAP3K8 lowest and highest quartile were compared (n= 36).
Similarly, highest en lowest quartile of serum amyloid A (SAA) and
C-reactive protein (CRP) levels were associated with MAP3K8
expression (n$30) (SAA: Q1#0.7 mg/L, Q4$1.6 mg/L; CRP.
Q1#0.5 mg/L, Q4$2.0 mg/L). All subjects gave written in-
formed consent. The study was approved by the ethical committee
of the Radboud University Medical Centre, Nijmegen.
Animals
MAP3K8-ko mice [13] and WT mice on a C57Bl/6
background were housed in a pathogen-free environment in the
animal facility from the Radboud University Nijmegen. All animal
procedures were conducted under protocols approved by the
animal experimentation committee of Radboud University
Nijmegen Medical Centre. Bodyweight of the animals was
recorded weekly. After a 2 weeks run-in period on low fat diet,
mice were given low fat diet (LFD) or high fat diet (HFD) feeding
for 16 weeks, containing 10% or 45% of energy derived from
palm oil fat (D125450B or 12451; Research Diets, Inc).
Figure 1. MAP3K8 in humans is associated with higher BMI and cytokine expression. MAP3K8 mRNA expression in human subcutaneous
adipose tissue, associated with (a) BMI, (b) plasma insulin values, (c) plasma glucose levels, (d) HOMA-IR, (e) adipocyte sell size cell size and (f) crown-
like structures. *p,0.05. n = 51, 50, 71, 70 respectively. HOMA-IR = Homeostatic Model Assessment for insulin resistance.
doi:10.1371/journal.pone.0089615.g001
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Oral glucose and insulin tolerance tests
Oral glucose tolerance (OGTT) and insulin tolerance tests (ITT)
were performed. Prior to the OGTT, animals were fasted
overnight (9 hours) and 2 g/kg glucose (D-glucose, Gibco,
Invitrogen) was orally administered. Prior to the ITT, mice were
fasted 6 hours and insulin (0,75 U/kg) was injected intraperitone-
ally. Blood glucose levels were determined with an Accu-chek
glucosemeter (Roche Diagnostics, Almere, The Netherlands) at
indicated time points after glucose administration.
Histochemistry
For detection of macrophages/monocytes, an F4/80+ antibody
(product code: MCA497G, AbD Serotec, Du¨sseldorf, Germany)
was used for mice samples, a CD68-monoclonal antibody (Clone
EBM11, Dako, Denmark) was used for human samples. Visual-
ization of the complex was done using 3,39-diaminobenzidene for
5 min. Negative controls were used by omitting the primary
antibody. Morphometry of individual fat cells was assessed using
digital image analysis. Microscopic images were digitized in 24-bit
RGB (specimen pixel size 1.2861.28 mm2). Recognition of fat cells
was initially performed by applying a region-growing algorithm on
manually indicated seed points, and minimum Feret diameter was
calculated.
qPCR
Total RNA was isolated from adipose tissue using TRIzol
(Invitrogen, Carlsbad, CA), according to manufacturer’s instruc-
tions. RNA was reverse-transcribed (iScript cDNA Synthesis Kit,
Bio-Rad Laboratories). RT-PCR was performed using specific
primers (see Table S1), power SYBR green master mix (Applied
Biosystems, Foster City, CA) using the Step-one Real-Time PCR
system (Applied Biosystems, Foster City, CA). For mice samples,
we used both 36B4 and GAPDH as housekeeping genes. For
human samples we used B2M as a housekeeping gene.
Western blot analysis
Lysis buffer (50 mM Tris (pH 7.4), 150 mMNaCl,
2 mMEDTA, 1% Nonidet P-40, 50 mMNaF, and 0.25% sodium
deoxycholate) with phosstop phosphatase-inhibitor cocktail tablet
(Roche) and complete, EDTA-free protease-inhibitor cocktail
tablet (Roche) was used to prepare adipose tissue lysates. The
homogenized lysate was then centrifuged at 4uC for 10 min at
Figure 2. MAP3K8 in humans is associated with IL-1b, IL-6 and IL-8 cytokine expression. Biopsies from subcutaneous adipose tissue were
obtained from healthy subjects with varying levels of obesity. Association of MAP3K8 mRNA expression in human subcutaneous adipose tissue with
mRNA expression of (a) IL-1ß, (b) IL-6, (c) IL-8, (d) TNF-a, (e) serum amyloid A levels (SAA: Q1#0.7 mg/L, Q4$1.6 mg/L), (f) C-reactive protein (CRP:
Q1#0.5 mg/L, Q4$2.0 mg/L). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0089615.g002
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18.000 rcf. Subsequently, the supernatant was used for Western
Blot. Equal amounts of protein as determined by a BCA protein
assay (Thermo FisherScientific, Rockford, IL) were loaded, and
separated using a polyacrylamide SDS page gel. After SDS-PAGE,
proteins were transferred to a nitrocellulose membrane using
Trans-Blot Turbo Transfer System (Biorad) following manufac-
turer’s instructions. The membrane was blocked for 1 h at room
temperature with 5% (wt/vol) milk powder in Tris-buffered saline
(TBS)/Tween 20. Subsequently, the membrane was incubated
overnight at 4uC with a phospho-p65 (Cell Signaling, 93H1) or
pan-p65 antibody (Cell Signaling, D14E12), phospho-ERK
(Promega, V8031) or pan-ERK antibody (Promega, V1141) and
a tubulin antibody (Santa Cruz Biotechnology, 2–28–33) in 5%
(wt/vol) milk powder/TBS/0.1% Tween 20. Hereafter, the blots
were incubated with horseradish peroxidase-conjugated secondary
antibodies (dilution of 1:5000) in 5% (wt/vol) milk powder in
TBS/0.1% Tween-20 for 1 h at room temperature and subse-
quently developed with Clarity reagent (Biorad) according to the
manufacturer’s instructions. Bands were visualized using a
ChemiDoc System (Biorad) and quantified using Image lab
software (Biorad).
Plasma proteins
Plasma concentrations of insulin (ultra sensitive mouse insulin
ELISA kit, Crystal Chem Inc., IL, USA; detection limit: 5 pg/ml)
were measured by ELISA according to the manufacturer’s
instructions. Mice CXCL-1 concentrations were determined
according to manufacturer’s instructions (Duoset, R&D systems,
MN, USA; detection limit 16 pg/ml). High sensitive C-reactive
protein (hsCRP) was measured by enzyme-immunoassay accord-
ing to the instructions from the manufacturer (Dako, Glastrup,
Denmark; detection limit 3.1 ng/ml). SAA was measured using
the N Latex SAA test (Siemens Healthcare Diagnostic, Germany,
detection limit: 0.02 ng/ml) according to the instructions from the
manufacturer.
Plasma glucose
Glucose (Liquicolor, Human GmbH, Wiesbaden, Germany)
was measured enzymatically following manufacturers’ protocols.
Statistical analysis
Data are shown as means 6 SEM. Differences between groups
were analyzed using Student’s t test, differences among 4 groups
were analyzed with ANOVA followed by post-hoc Bonferroni tests
in Graphpad Prism 5.0. p-values ,0.05 were considered
significant.
Results
BMI, IL-6 and IL-8 expression are associated with higher
MAP3K8 expression in human adipose tissue
First, we determined the association of MAP3K8 (TPL2/COT)
expression in human adipose tissue with measures of obesity
(BMI), adipose tissue inflammation (cytokine expression) and
insulin resistance (plasma insulin). Human subcutaneous tissue
biopsies were acquired from healthy subjects with a wide range in
BMI. As shown in Figure 1a, mRNA expression levels of
MAP3K8 were significantly higher in individuals with a BMI
higher than 30, compared to subjects with a normal BMI (between
20–25 kg/m2). However, no differences in MAP3K8 expression
were observed between persons with low versus high plasma
insulin and glucose levels (Fig. 1b/c). In line with this, no
Figure 3. Obesity and macrophage influx in adipose tissue of HFD-fedWT andMAP3K8-ko animals.MAP3K8-ko and WT mice were fed a
LFD or HFD during 16 weeks. (a) Bodyweight development upon LFD or HFD feeding. (b) Epididymal white adipose tissue (eWAT) weight after
16 weeks of LFD or HFD. (c) Liver weight after 16 weeks of LFD or HFD. (d) Plasma CXCL1 levels after 16 weeks of LFD or HFD (e) Macrophage influx
into the adipose tissue as determined by immunohistochemistry, F4/80 (serotec) staining: 206magnification or 406 as indicated: (f) Number of
crown-like structures per field. (g–i) qPCR analysis for macrophage infiltration markers, (g) CD68, (h) F4/80, (i) MCP-1 in adipose tissue of MAP3K8-ko
and WT animals. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0089615.g003
MAP3K8 and Obesity in Humans and Mice
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differences were observed for MAP3K8 expression in subjects with
increased insulin resistance, as calculated by the homeostatic
model for insulin resistance (Fig. 1d). Moreover, we did not see an
increased expression of MAP3K8 in subjects with small versus
large adipocyte size (Fig. 1e) or in subjects with crown-like
structures (CLS) formed by infiltrating CD68 positive macrophag-
es in adipose tissue compared to subjects with no CLS (Fig. 1f).
Interestingly, we found that higher mRNA expression of IL-1ß
in human adipose tissue was associated with higher mRNA levels
of MAP3K8, although this difference did not reach statistical
significance, p = 0.063 (Fig. 2a). Moreover, mRNA expression
levels of IL-1ß responsive cytokines, IL-6 and IL-8, were
significantly associated with higher MAP3K8 expression
(Fig. 2b/c). In contrast, TNFa mRNA levels did not associate
with MAP3K8 expression (Fig. 2d). Moreover, systemic inflam-
matory markers were measured in the plasma and related to
MAP3K8 expression in adipose tissue. Higher levels of serum
amyloid A (SAA) were negatively associated with MAP3K8
expression in adipose tissue (Fig. 2e). In contrast, no relation
was measured for MAP3K8 expression and plasma C-reactive
protein (CRP) levels (Fig. 2f).
MAP3K8-ko mice show similar body weight compared to
WT mice
Based on the association of higher MAP3K8 expression with
both BMI and enhanced levels of IL-1ß responsive genes in
human adipose tissue, we set out to determine if MAP3K8 causally
affects obesity and adipose tissue inflammation in vivo. Therefore,
12-week old MAP3K8 deficient or WT mice, were fed a high-fat
diet (HFD, 45% calories by energy content derived from fat) or
low-fat diet (LFD, 10%) for 16 weeks. Although MAP3K8-ko mice
gained bodyweight faster during the initial phase of the diet
intervention, at the end of the study there were no differences in
bodyweight between MAP3K8-ko and WT mice (Figure 3a). At
the end of the intervention period, both genotypes gained
approximately 9–10 grams more bodyweight due to the HFD-
Figure 4. Inflammatory profile of the adipose tissue of HFD-fed WT and MAP3K8-ko animals.MAP3K8-ko and WT mice were fed a LFD or
HFD during 16 weeks. (a–f) qPCR analysis for cytokines (a) TNF-a, (b) IFNc, (c) IL-1b, (d) CXCL-1, (e) IL-6 and (f) IL-1Ra. n = 9 mice per group. Relative
phosphorylation of NFkB p65 (g) and ERK 1/2 (h) in eWAT of MAP3K8-ko and WT animals after HFD-feeding (i). * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0089615.g004
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feeding, compared to the LFD intervention. Moreover, MAP3K8-
ko and WT mice had a similar epididymal white adipose tissue
(eWAT) and liver weight after HFD feeding (Fig. 3b/c).
Interestingly, MAP3K8-ko mice had a significant higher eWAT
weight after LFD.
Different mRNA expression profile of inflammatory in
adipose tissue
Next, we investigated whether MAP3K8-deficiency affected
inflammation in response to HFD feeding. Indeed, in WT mice
systemic CXCL-1 levels were increased after HFD-feeding.
However, this effect was blunted in MAP3K8ko mice (Fig. 3d).
Adipose tissue sections were stained for F4/80 and the amount of
crown-like structures (CLS) in the adipose tissue was counted
(Fig. 3e). HFD feeding significantly increased the amount of CLS
in adipose tissue similarly, in both MAP3K8-ko and WT mice
(Fig. 3f). Interestingly, mRNA expression levels of the macro-
phage markers CD68 and F4/80 were significantly higher in
MAP3K8-ko mice, while expression of MCP-1 was similar
between both genotypes upon HFD feeding (Fig. 3g–i).
In line with an increased expression of macrophage markers,
TNF-a and IFNc mRNA levels tended to be increased in
MAP3K8-ko mice fed a HFD, although this change did not reach
statistical significance for IFNc (Fig. 4a/b). In contrast, HFD-
feeding did not upregulate expression of IL-1b and IL-1 effector
cytokines IL-6 and CXCL-1 in MAP3K8-ko mice (Fig. 4c–e).
Furthermore, mRNA IL-1Ra levels were not changed in
MAP3K8-ko mice as compared to WT animals (Fig. 4f). To
determine whether intracellular downstream targets of inflamma-
tory pathways were affected in MAP3K8-ko versus WT mice,
western blots were performed to measure the presence of
phosphorylated ERK1/2 and NF-kB p65 in adipose tissue of
both genotypes after HFD-feeding. No changes were observed in
relative phosphorylation of both ERK1/2 and NF-kB p65
(Fig. 4g/h) as shown in Figure 4i.
Figure 5. MAP3K8-ko mice display similar bodyweight and insulin sensitivity compared to WT mice. MAP3K8-ko and WT mice were fed
a LFD or HFD during 16 weeks. (a) Plasma insulin and (b) plasma glucose levels after diet intervention. Insulin (itt) and oral glucose (ogtt) tolerance
tests after 16 weeks of diet intervention. (c) itt after 16 weeks of HFD and (d) area under the curve itt. (e) ogtt after 16 weeks of HFD and (f) area
under the curve of ogtt. n = 9 mice per group. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0089615.g005
MAP3K8 and Obesity in Humans and Mice
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MAP3K8-ko and WT display similar glucose and insulin
tolerance after HFD
Next, we investigated whether the changes in adipose tissue
inflammation in MAP3K8-ko and WT mice influence systemic
insulin sensitivity. HFD-feeding increased fasting plasma insulin
levels in WT, but not MAP3K8-ko mice (Fig. 5a). In contrast,
basal plasma glucose levels were increased in MAP3K8-ko mice
after HFD compared to WT on the same diet (Fig. 5b). To
investigate whether insulin and glucose homeostasis was different
in MAP3K8-ko and WT mice, we subjected the mice to an oral
glucose tolerance test (ogtt) and insulin tolerance test (itt). As
shown in Figures 5c–fMAP3K8 deficiency did not affect glucose
or insulin tolerance upon LFD or HFD feeding. Notably,
MAP3K8-ko mice fed a HFD even displayed a worsening if
insulin tolerance as determined by the area under the curve
(AUC), although this finding is partially explained by the elevated
basal plasma glucose level.
Discussion
Inflammation plays a pivotal role in the development of insulin
resistance associated with obesity. MAP3K8 (TPL2/COT) has
been suggested to be an interesting therapeutic target in order to
reduce inflammation, as it regulates activation of NF-kB and JNK
transcription factors. Indeed, we observed that the mRNA
expression of pro-inflammatory cytokines IL-1ß, IL-6 and IL-8
are associated with expression of MAP3K8 mRNA in human
adipose tissue. However, our results do not reveal any association
of MAP3K8 expression with markers of insulin sensitivity in
human subjects and do not support a crucial role for MAP3K8 as
an important regulator in the development of insulin resistance
during obesity in mice. The results of this study show that human
MAP3K8 adipose tissue expression is positively associated with
BMI and expression of several pro-inflammatory cytokines in
adipose tissue, but not with systemic inflammatory- or metabolic
parameters such as plasma SAA, CRP, insulin or glucose levels.
Similarly, although absence of MAP3K8 in mice induced mild
changes in inflammation in adipose tissue, there were no
differences in systemic insulin resistance even after 16 weeks of a
HFD intervention. Therefore, these findings suggest that other
inflammatory pathways or kinases may play a more dominant role
in the development of obesity induced inflammation and insulin
resistance. Hence, MAP3K8 may restrict its role to mediating local
cytokine secretion as a downstream kinase of pivotal inflammatory
receptors, but without affecting systemic metabolic parameters.
Although MAP3K8 has been reported to be an important
regulator of inflammatory pathways in other diseases [14], the
effect of MAP3K8 on obesity-induced chronic low-grade inflam-
mation has been a point of debate. Three prior studies have
provided contradictory evidence for the role of MAP3K8 in
obesity-induced inflammation and metabolic dysfunction [10–12].
We found that MAP3K8 is upregulated in human adipose tissue in
obese individuals. Moreover, we demonstrate an association
between higher MAP3K8 mRNA expression and both IL-1ß
and the IL-1ß -responsive cytokines IL-6 and IL-8 in the adipose
tissue. MAP3K8 expression levels are not associated with a general
enhancement in the inflammatory status of the adipose tissue as
mRNA levels of the pro-inflammatory cytokine TNF-a are not
changed between the low and high MAP3K8 expressing groups.
Although TNF-a is known to be dependent on MAP3K8 in
macrophages [9,15], TNF-a can also be produced independently
of MAP3K8 [15,16]. Moreover, systemic inflammatory markers
SAA and CRP were not positively associated with increased
MAP3K8 adipose tissue levels, suggestive of a redundant role of
MAP3K8 in obesity-induced low-grade systemic inflammation.
Furthermore, we show that MAP3K8-ko and WT mice do not
differ in weight after 16 weeks of high fat diet feeding, and that
liver weight is similar as well, which is in accordance with earlier
studies ([11] [12]). In the present study, the MAP3K8-ko mice did
not show ameliorated inflammation in the adipose tissue in
response to HFD, which is similar to findings of Lancaster et al. but
opposed to the study of Perfield et al. In fact, expression levels of
several macrophage markers (F480, CD68) were higher in adipose
tissue of MAP3K8-ko mice compared to WT mice, suggesting
increased macrophage infiltration. Interestingly, we observed that
expression levels of IL-1ß and IL-1ß effector cytokines (CXCL1
and IL-6) were downregulated, leading to a reduction in
circulating plasma CXCL1 levels. Since these cytokines are
known to be activated via NFkB and ERK signaling, the
reduction in cytokine expression could be secondary to a reduced
activation of NFkB or ERK that are downstream molecules of
MAP3K8 [14,16,17]. However, no difference in activation of
NFkB or ERK 1/2 was found, suggesting that these downstream
mediators of MAP3K8 were not differently regulated after HFD in
both genotypes, hence other molecules downstream of MAP3K8
may be of more importance. The enhanced expression of
macrophage markers in absence of MAP3K8 may be a
compensatory mechanism for the inhibited cytokine expression
by adipose tissue macrophages. Moreover, the increase of TNF-a
and IFN-c expression in adipose tissue in the MAP3K8-ko mice,
might explain that no differences are seen on systemic metabolic
parameters via compensatory mechanisms, as indicated by
unchanged insulin or glucose tolerance in the MAP3K8-ko mice.
Together, these results show that absence of MAP3K8 may affect
certain inflammatory pathways and macrophage infiltration, but
does not affect the presence of crown-like structures or systemic
insulin sensitivity. Interestingly, our current results show that
insulin levels in the MAP3K8-ko mice are lower, probably
explaining a higher fasting glucose level, as was reported before.
It may be worthwhile in the future to investigate the effect of
MAP3K8 on insulin secretion of the pancreas. Hence, in line with
the lower expression levels of IL-1ß that is known to affect beta-cell
function [18] the absence of MAP3K8 may affect insulin
production.
Parts of our results differ from earlier findings, which may be
explained by different experimental or housing conditions. Gut
microbiota is suggested to contribute to adipose tissue inflamma-
tion and metabolic disease [19]. Therefore, differences in
microbiota composition may exist between facilities and could
contribute to opposing. In addition, some studies used different
types of high fat diets. Another possible explanation is that in the
study of Perfield et al., mice were given a high fat diet from
6 weeks of age, while in this study and the study of Lancaster, the
mice were several weeks older at the start of the diet intervention.
Importantly, in our study, data from mice experiments were in
agreement with data derived from human adipose tissue biopsies,
confirming a positive association of MAP3K8 expression with local
cytokine expression, but not with systemic metabolic parameters.
In summary, these data show that MAP3K8 has a limited role
in obesity-induced inflammation and support earlier results by
Lancaster et al. [12], who did not see protection against obesity-
induced metabolic disease in knock-out mice. Altogether, the
findings argue against MAP3K8 to be a central kinase in
regulating pro-inflammatory signals leading to insulin resistance.
For the first time, we show an association between adipose tissue
expression of MAP3K8 and IL-1ß, IL-6 and IL-8 in humans. In
line with this, our data reveal that MAP3K8 deficiency in HFD-
MAP3K8 and Obesity in Humans and Mice
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fed mice reduces adipose tissue expression of IL-1ß, IL-6 and IL-8.
Therefore, we propose that MAP3K8 may affect production of
specific cytokines in adipose tissue inflammation during develop-
ment of obesity, but that these changes do not translate to
profound systemic effects. Although we cannot rule out an effect
on insulin sensitivity upon specific inhibition of the MAP3K8
signalling pathway during obesity, future studies should rather
illuminate the role of other inflammatory pathways and kinases in
adipose tissue affecting systemic metabolic health.
Supporting Information
Table S1 List of primers used for RT-PCR. Primer
sequence for all human and mouse genes are listed in this table.
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